MAUI, Hawaii, March 27 /PRNewswire-FirstCall/ --
Bioponic Phytoceuticals, Inc. ("Bioponic" or "the Company") (OTC: BPYT - News) today announced that its Curecumin(TM) (a Bioresonant Phytotherapeutic® form of Turmeric containing curcumin in a liquid nasal delivery system) may be an important treatment for Lung Cancer.
In a recent study published in Science Direct, "Induction of Apoptosis in Human Lung Cancer Cells by Curcumin," conducted at the Department of Medicine, Pediatrics and Family and Preventive Medicine, School of Medicine, University of California, San Diego, scientists concluded, "Curcumin, a phenolic compound from the rhizome of the plant Curcuma longa has anti-inflammatory, antioxidant and anti-cancer activities... This study investigated the cellular and molecular changes induced by curcumin leading to the induction of apoptosis in human lung cancer cell lines -- A549 and H1299... Curcumin inhibited the growth of both the cell lines in a concentration dependent manner... Curcumin induced apoptosis in both the lung cancer cell lines."
"We are particularly interested in the potential of our Curecumin(TM) product to provide a viable treatment strategy for those with lung cancer. Especially, because the liquid form of Curecumin, in a nasal delivery system, will send the formula directly to the lungs. If proven effective, we may have an efficacious, cost effective, natural treatment for lung cancer sufferers." said Steven M. Schorr, Chairman & CEO -- Bioponic Phytoceuticals, Inc.
Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products for sale in the Complementary Alternative Medicine ("CAM") and natural products markets. The Company has developed several branded product lines in distribution (including the nationally recognized natural nasal spray: Flight Spray). Bioponic is focused on the production of natural products that are used to promote health and well-being. www.bioponic.com Contact: Steven M. Schorr/ CEO, Bioponic Phytoceuticals, firstname.lastname@example.org, ph: 808-876-1711